CA2962691C - Methods for assessing risk of developing breast cancer - Google Patents

Methods for assessing risk of developing breast cancer Download PDF

Info

Publication number
CA2962691C
CA2962691C CA2962691A CA2962691A CA2962691C CA 2962691 C CA2962691 C CA 2962691C CA 2962691 A CA2962691 A CA 2962691A CA 2962691 A CA2962691 A CA 2962691A CA 2962691 C CA2962691 C CA 2962691C
Authority
CA
Canada
Prior art keywords
risk
breast cancer
single nucleotide
subject
clinical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2962691A
Other languages
English (en)
French (fr)
Other versions
CA2962691A1 (en
Inventor
Richard Allman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Technologies Ltd
Original Assignee
Genetic Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903898A external-priority patent/AU2014903898A0/en
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of CA2962691A1 publication Critical patent/CA2962691A1/en
Application granted granted Critical
Publication of CA2962691C publication Critical patent/CA2962691C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
CA2962691A 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer Active CA2962691C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903898 2014-09-30
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (2)

Publication Number Publication Date
CA2962691A1 CA2962691A1 (en) 2016-04-07
CA2962691C true CA2962691C (en) 2023-05-23

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2962691A Active CA2962691C (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Country Status (11)

Country Link
US (2) US10920279B2 (enExample)
EP (1) EP3201360A4 (enExample)
JP (1) JP6820838B2 (enExample)
KR (1) KR102334702B1 (enExample)
CN (1) CN107002138B (enExample)
AU (2) AU2015327756B2 (enExample)
CA (1) CA2962691C (enExample)
IL (1) IL251376B (enExample)
MX (1) MX392267B (enExample)
SG (1) SG11201702416YA (enExample)
WO (1) WO2016049694A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103710430B (zh) 2005-11-29 2016-03-30 剑桥企业有限公司 乳腺癌标志物
MX2011012913A (es) 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
IL251376B (en) 2014-09-30 2022-09-01 Genetic Tech Limited Methods for assessing risk of developing breast cancer
CA3051488A1 (en) * 2017-01-24 2018-08-02 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
KR20200100614A (ko) * 2017-10-13 2020-08-26 지네틱 테크놀로지스 리미티드 유방암 발생의 위험도 평가의 방법
CN108060229A (zh) * 2017-12-27 2018-05-22 沃森克里克（北京）生物科技有限公司 一种TERT基因rs10069690位点SNP核酸质谱检测方法
CN110628912A (zh) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 检测多态性的引物及方法
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
CA3179313A1 (en) * 2020-05-27 2021-12-02 Gillian Sue Dite Methods of assessing risk of developing a severe response to coronavirus infection
CN112687330A (zh) * 2020-12-29 2021-04-20 北京易奇科技有限公司 一种乳腺癌患者携带胚系致病变异的风险预测系统
CN115719613A (zh) * 2021-12-27 2023-02-28 河北北方学院附属第一医院 基于分子标记的用于肝癌筛查和风险预测的系统及应用
US20250149176A1 (en) * 2023-11-08 2025-05-08 Optum Services (Ireland) Limited Model-based risk prediction and treatment pathway prioritization

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
AU726501B2 (en) 1996-06-04 2000-11-09 University Of Utah Research Foundation Monitoring hybridization during PCR
WO1998020167A1 (en) 1996-11-07 1998-05-14 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
MXPA01005513A (es) 1998-12-02 2003-07-14 Dna Sciences Inc Metodos para reducir la variacion en estudios de tratamiento utilizando genotipificacion.
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
CA2417407A1 (en) 2000-07-25 2002-01-31 Dz Genes Llc Diagnostic polymorphisms for the ecnos promoter
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
WO2005024067A2 (en) 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
CN103710430B (zh) 2005-11-29 2016-03-30 剑桥企业有限公司 乳腺癌标志物
WO2007150044A2 (en) 2006-06-23 2007-12-27 Intergenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
CN101874120B (zh) 2007-03-26 2015-01-14 解码遗传学私营有限责任公司 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
EP2164984A2 (en) 2007-05-25 2010-03-24 Decode Genetics EHF. Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2176426A2 (en) 2007-07-11 2010-04-21 InterGenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
AU2009279434A1 (en) 2008-08-08 2010-02-11 Navigenics, Inc. Methods and systems for personalized action plans
BRPI0918889A2 (pt) 2008-09-12 2015-12-01 Navigenics Inc método para gerar uma pontuação de um índice composto genético ambiental (egci) para uma doença ou condição de um indivíduo
MX2011012913A (es) * 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
WO2010151841A2 (en) * 2009-06-25 2010-12-29 Yale University Single nucleotide polymorphisms in brca1 and cancer risk
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
IL251376B (en) 2014-09-30 2022-09-01 Genetic Tech Limited Methods for assessing risk of developing breast cancer
CA3051488A1 (en) 2017-01-24 2018-08-02 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
KR20200100614A (ko) 2017-10-13 2020-08-26 지네틱 테크놀로지스 리미티드 유방암 발생의 위험도 평가의 방법

Also Published As

Publication number Publication date
AU2015327756B2 (en) 2018-01-04
CN107002138A (zh) 2017-08-01
IL251376B (en) 2022-09-01
AU2018202299B9 (en) 2020-03-05
MX392267B (es) 2025-03-24
SG11201702416YA (en) 2017-04-27
JP2017529859A (ja) 2017-10-12
US10920279B2 (en) 2021-02-16
MX2017004127A (es) 2017-10-24
AU2018202299B2 (en) 2019-10-24
EP3201360A1 (en) 2017-08-09
US10683549B2 (en) 2020-06-16
US20180305764A1 (en) 2018-10-25
KR102334702B1 (ko) 2021-12-06
JP6820838B2 (ja) 2021-01-27
AU2015327756A1 (en) 2017-04-13
CA2962691A1 (en) 2016-04-07
WO2016049694A1 (en) 2016-04-07
CN107002138B (zh) 2022-06-14
AU2018202299A1 (en) 2018-04-26
US20160222469A1 (en) 2016-08-04
IL251376A0 (en) 2017-05-29
KR20170063977A (ko) 2017-06-08
EP3201360A4 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
AU2018202299B9 (en) Methods for assessing risk of developing breast cancer
EP3408412B1 (en) Methods for assessing risk of developing colorectal cancer
US20200102617A1 (en) Improved Methods For Assessing Risk of Developing Breast Cancer
AU2022279367A1 (en) Methods of assessing risk of developing breast cancer
AU2022407711A1 (en) Breast cancer risk assessment
HK40001097B (en) Methods for assessing risk of developing colorectal cancer
HK40001097A (en) Methods for assessing risk of developing colorectal cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928